



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SP/2024-25/92

September 21, 2024

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol - Biocon
--	---

Dear Sir/Madam,

Subject: Notification to Stock Exchanges

This is to inform you that *“the U.S. Food and Drug Administration (US FDA) conducted a surveillance inspection of our API facility (Site 1), located at Bengaluru, Karnataka, between the 16th to 20th September 2024.*

Three observations were cited at the end of the Inspection, which the Company will be addressing within the stipulated time. The Company does not foresee any impact on the business.”

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer
Membership No. A18776